European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Research output: Contribution to journal › Review › Research › peer-review

Standard

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. / Frisoni, Giovanni B.; Festari, Cristina; Massa, Federico; Cotta Ramusino, Matteo; Orini, Stefania; Aarsland, Dag; Agosta, Federica; Babiloni, Claudio; Borroni, Barbara; Cappa, Stefano F.; Frederiksen, Kristian S.; Froelich, Lutz; Garibotto, Valentina; Haliassos, Alexander; Jessen, Frank; Kamondi, Anita; Kessels, Roy PC; Morbelli, Silvia D.; O'Brien, John T.; Otto, Markus; Perret-Liaudet, Armand; Pizzini, Francesca B.; Vandenbulcke, Mathieu; Vanninen, Ritva; Verhey, Frans; Vernooij, Meike W.; Yousry, Tarek; Boada Rovira, Mercè; Dubois, Bruno; Georges, Jean; Hansson, Oskar; Ritchie, Craig W.; Scheltens, Philip; van der Flier, Wiesje M.; Nobili, Flavio.

In: The Lancet Neurology, Vol. 23, No. 3, 2024, p. 302-312.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Frisoni, GB, Festari, C, Massa, F, Cotta Ramusino, M, Orini, S, Aarsland, D, Agosta, F, Babiloni, C, Borroni, B, Cappa, SF, Frederiksen, KS, Froelich, L, Garibotto, V, Haliassos, A, Jessen, F, Kamondi, A, Kessels, RPC, Morbelli, SD, O'Brien, JT, Otto, M, Perret-Liaudet, A, Pizzini, FB, Vandenbulcke, M, Vanninen, R, Verhey, F, Vernooij, MW, Yousry, T, Boada Rovira, M, Dubois, B, Georges, J, Hansson, O, Ritchie, CW, Scheltens, P, van der Flier, WM & Nobili, F 2024, 'European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders', The Lancet Neurology, vol. 23, no. 3, pp. 302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

APA

Frisoni, G. B., Festari, C., Massa, F., Cotta Ramusino, M., Orini, S., Aarsland, D., Agosta, F., Babiloni, C., Borroni, B., Cappa, S. F., Frederiksen, K. S., Froelich, L., Garibotto, V., Haliassos, A., Jessen, F., Kamondi, A., Kessels, R. PC., Morbelli, S. D., O'Brien, J. T., ... Nobili, F. (2024). European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Lancet Neurology, 23(3), 302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

Vancouver

Frisoni GB, Festari C, Massa F, Cotta Ramusino M, Orini S, Aarsland D et al. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Lancet Neurology. 2024;23(3):302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

Author

Frisoni, Giovanni B. ; Festari, Cristina ; Massa, Federico ; Cotta Ramusino, Matteo ; Orini, Stefania ; Aarsland, Dag ; Agosta, Federica ; Babiloni, Claudio ; Borroni, Barbara ; Cappa, Stefano F. ; Frederiksen, Kristian S. ; Froelich, Lutz ; Garibotto, Valentina ; Haliassos, Alexander ; Jessen, Frank ; Kamondi, Anita ; Kessels, Roy PC ; Morbelli, Silvia D. ; O'Brien, John T. ; Otto, Markus ; Perret-Liaudet, Armand ; Pizzini, Francesca B. ; Vandenbulcke, Mathieu ; Vanninen, Ritva ; Verhey, Frans ; Vernooij, Meike W. ; Yousry, Tarek ; Boada Rovira, Mercè ; Dubois, Bruno ; Georges, Jean ; Hansson, Oskar ; Ritchie, Craig W. ; Scheltens, Philip ; van der Flier, Wiesje M. ; Nobili, Flavio. / European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. In: The Lancet Neurology. 2024 ; Vol. 23, No. 3. pp. 302-312.

Bibtex

@article{7fcb4a4eef104e09aca559a310dda3f7,
title = "European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders",
abstract = "The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.",
author = "Frisoni, {Giovanni B.} and Cristina Festari and Federico Massa and {Cotta Ramusino}, Matteo and Stefania Orini and Dag Aarsland and Federica Agosta and Claudio Babiloni and Barbara Borroni and Cappa, {Stefano F.} and Frederiksen, {Kristian S.} and Lutz Froelich and Valentina Garibotto and Alexander Haliassos and Frank Jessen and Anita Kamondi and Kessels, {Roy PC} and Morbelli, {Silvia D.} and O'Brien, {John T.} and Markus Otto and Armand Perret-Liaudet and Pizzini, {Francesca B.} and Mathieu Vandenbulcke and Ritva Vanninen and Frans Verhey and Vernooij, {Meike W.} and Tarek Yousry and {Boada Rovira}, Merc{\`e} and Bruno Dubois and Jean Georges and Oskar Hansson and Ritchie, {Craig W.} and Philip Scheltens and {van der Flier}, {Wiesje M.} and Flavio Nobili",
note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",
year = "2024",
doi = "10.1016/S1474-4422(23)00447-7",
language = "English",
volume = "23",
pages = "302--312",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "TheLancet Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

AU - Frisoni, Giovanni B.

AU - Festari, Cristina

AU - Massa, Federico

AU - Cotta Ramusino, Matteo

AU - Orini, Stefania

AU - Aarsland, Dag

AU - Agosta, Federica

AU - Babiloni, Claudio

AU - Borroni, Barbara

AU - Cappa, Stefano F.

AU - Frederiksen, Kristian S.

AU - Froelich, Lutz

AU - Garibotto, Valentina

AU - Haliassos, Alexander

AU - Jessen, Frank

AU - Kamondi, Anita

AU - Kessels, Roy PC

AU - Morbelli, Silvia D.

AU - O'Brien, John T.

AU - Otto, Markus

AU - Perret-Liaudet, Armand

AU - Pizzini, Francesca B.

AU - Vandenbulcke, Mathieu

AU - Vanninen, Ritva

AU - Verhey, Frans

AU - Vernooij, Meike W.

AU - Yousry, Tarek

AU - Boada Rovira, Mercè

AU - Dubois, Bruno

AU - Georges, Jean

AU - Hansson, Oskar

AU - Ritchie, Craig W.

AU - Scheltens, Philip

AU - van der Flier, Wiesje M.

AU - Nobili, Flavio

N1 - Publisher Copyright: © 2024 Elsevier Ltd

PY - 2024

Y1 - 2024

N2 - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

AB - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

U2 - 10.1016/S1474-4422(23)00447-7

DO - 10.1016/S1474-4422(23)00447-7

M3 - Review

C2 - 38365381

AN - SCOPUS:85185269773

VL - 23

SP - 302

EP - 312

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 3

ER -

ID: 384254871